PFM Health Sciences’s Allogene Therapeutics ALLO Stock Holding History

PFM Health Sciences’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-246,000	Closed	-$8.68M	–	85
2021 Q1	$8.68M	Buy	+246,000	New	+$8.3M	0.27%	68

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PFM Health Sciences's ALLO Position: Q4 2021 in Review

PFM Health Sciences sold out of Allogene Therapeutics (ALLO) in Q4 2021, closing a stake of 775,819 shares — an estimated $19.9M sold.

PFM Health Sciences first reported a position in ALLO in Q4 2018 and held it in 5 quarters. The position peaked at $20.8M in Q1 2021. 177 funds tracked by Wall St. Rank hold ALLO as of Q4 2021.

PFM Health Sciences reported no remaining Allogene Therapeutics position as of Q4 2021 after selling out during the quarter.
PFM Health Sciences sold 775,819 Allogene Therapeutics shares in Q4 2021, an estimated $19.9M.
PFM Health Sciences first reported a position in Allogene Therapeutics in Q4 2018 and held it in 5 quarters.
PFM Health Sciences's Allogene Therapeutics position peaked at $20.8M in Q1 2021.
177 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2021.

Based on PFM Health Sciences's 13F filing for Q4 2021, filed 14 Feb 2022.